<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02237586</url>
  </required_header>
  <id_info>
    <org_study_id>LACHMI-001</org_study_id>
    <nct_id>NCT02237586</nct_id>
  </id_info>
  <brief_title>Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge</brief_title>
  <official_title>Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanaria Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Recherche Médicale de Lambaréné</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, University of Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanaria Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to establish infectivity of Plasmodium falciparum sporozoites (PfSPZ)&#xD;
      via intravenous (IV) administration in three groups with different malaria immunity-status:&#xD;
&#xD;
        1. Adults with a history of lifelong malaria exposure without sickle cell trait (HbAA)&#xD;
&#xD;
        2. Adults with a history of lifelong malaria exposure with sickle cell trait (HbAS)&#xD;
&#xD;
        3. Adults without previous malaria episodes without sickle cell trait (HbAA)&#xD;
&#xD;
      Initially a dose of 3,200 PfSPZ will be given and the time until thick blood smear positivity&#xD;
      after challenge will be assessed. If in any of the groups with a history of lifelong malaria&#xD;
      exposure, 50% or less of individuals become thick blood smear positive during the 28 days&#xD;
      post injection of PfSPZ Challenge, the dose will be increased 4-fold to 12,800 PfSPZ in this&#xD;
      group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LACHMI-001 is a partially-blinded, human pilot trial to study immunity against P. falciparum&#xD;
      malaria in a controlled infection setting. The main objective is to characterise the role of&#xD;
      sickle cell trait and naturally acquired immunity in development of malaria, defined by&#xD;
      positive smear for P. falciparum and signs or symptoms associated with malaria. Three groups&#xD;
      of volunteers will receive radical cure treatment and subsequently PfSPZ Challenge by IV&#xD;
      administration. The groups are:&#xD;
&#xD;
        1. Adults with naturally acquired immunity and HbAA (Group IA, n=10-20)&#xD;
&#xD;
        2. Adults with naturally acquired immunity and HbAS (Group IS, n=10-20)&#xD;
&#xD;
        3. Adults without previous exposure to malaria and HbAA (Group NI, n=5)&#xD;
&#xD;
      The initial challenge dose of 3,200 PfSPZ administered once intravenously leads to consistent&#xD;
      infection in naïve adults (15/15 in prior studies) and thus should infect all volunteers in&#xD;
      Group 3. However, volunteers with naturally acquired immunity or sickle cell trait might&#xD;
      require a higher dose. Thus if 50% or less of volunteers become parasitemic in Groups IA or&#xD;
      IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. All&#xD;
      volunteers will be healthy adults aged 18 to 30 years. Safety and infectivity data will be&#xD;
      collected for each of the regimens and dose-levels. Effective treatment is initiated&#xD;
      immediately upon development of parasitemia together with the presence of symptoms associated&#xD;
      with malaria.&#xD;
&#xD;
      Laboratory staff reading blood films and processing samples will be blinded to group&#xD;
      allocation. Volunteers and clinical investigators will be blinded to group allocation among&#xD;
      the IA and IS groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days from inoculation to start of malaria episode</measure>
    <time_frame>From day of injection until day 28</time_frame>
    <description>The time from parasite inoculation to first detection of malaria will be assessed by thick blood film microscopy and a clinical questionnaire. Malaria is defined as both parasitemia and clinical symptoms suggestive of malaria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency, incidence and nature of adverse events</measure>
    <time_frame>From day of injection until day 28</time_frame>
    <description>The safety of PfSPZ Challenge administered IV and the resultant P. falciparum infection will be assessed by analysing actively and passively collected data from clinical review of volunteers and laboratory measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dynamics of P. falciparum parasite growth</measure>
    <time_frame>From day 6 after injection until approximately day 28</time_frame>
    <description>The dynamics of P. falciparum parasite growth following administration of PfSPZ Challenge is assessed by analyzing parasite multiplication rates using highly sensitive qPCR for P. falciparum DNA. Measurements will be used to model parasite kinetics and to estimate the number of infected liver cells.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cellular and humoral immune responses against parasites</measure>
    <time_frame>From screening until 6 months</time_frame>
    <description>Cellular and humoral immune responses against parasites will be assessed by individual and collective results of cytometry, enzyme-linked immunospot analysis (ELISpot), enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), inhibition of sporozoite invasion of hepatocytes assay (ISI), quantification of erythrophagocytosis, B-cell typing and isolation as well as protein microarray.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stage specific expression patterns of parasite genes</measure>
    <time_frame>From screening until 6 months</time_frame>
    <description>Stage specific expression patterns of parasite genes will be assessed by RNA quantification using reverse transcriptase PCR (rtPCR) and transcriptional profiling on microarray and sequencing platforms. Differences in miRNA expression between AA and AS erythrocytes will be determined and related to multiplication rates.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Plasmodium Falciparum Malaria</condition>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Group IA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults with naturally acquired immunity and HbAA (Group IA, n=10)&#xD;
As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults with naturally acquired immunity and HbAS (Group IS, n=10)&#xD;
As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group NI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults without previous exposure to malaria and HbAA (Group NI, n=5)&#xD;
As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge administered once intravenously should lead to consistent infection in naïve adults (15/15 in prior studies) and thus should infect all volunteers in Group NI. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PfSPZ Challenge</intervention_name>
    <description>live, aseptic, cryopreserved P. falciparum sporozoites</description>
    <arm_group_label>Group IA</arm_group_label>
    <arm_group_label>Group IS</arm_group_label>
    <arm_group_label>Group NI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult aged 18 to 30 years&#xD;
&#xD;
          -  Able and willing (in the investigator's opinion) to comply with all study requirements&#xD;
&#xD;
          -  Women only: must agree to practice continuous effective contraception for the duration&#xD;
             of the study (a method which results in a low failure rate; i.e. less than 1% per&#xD;
             year)&#xD;
&#xD;
          -  Agreement to refrain from blood donation during the course of the study and after the&#xD;
             end of their involvement in the study according to the local blood banking eligibility&#xD;
             criteria&#xD;
&#xD;
          -  Written informed consent to undergo CHMI&#xD;
&#xD;
          -  Reachable (24/7) by mobile phone during the whole study period&#xD;
&#xD;
          -  Willingness to take two curative anti-malarial regimens&#xD;
&#xD;
          -  Agreement to stay overnight for observation during the period of intensive follow-up&#xD;
             post-challenge if required&#xD;
&#xD;
          -  Answer all questions on the informed consent quiz correctly&#xD;
&#xD;
          -  A body mass index &lt; 35&#xD;
&#xD;
          -  A haemoglobin concentration ≥10 g/dl for women and ≥12 g/dl for men&#xD;
&#xD;
        Additional inclusion criteria for IA and IS group only:&#xD;
&#xD;
        - History of long term residence (&gt;10 years) in area known to have significant transmission&#xD;
        of P. falciparum -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of anti-malarials within 30 days of study enrolment&#xD;
&#xD;
          -  Use of systemic antibiotics with known antimalarial activity within 30 days of study&#xD;
             enrolment (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin,&#xD;
             erythromycin, fluoroquinolones, or azithromycin)&#xD;
&#xD;
          -  Receipt of an investigational product in the 30 days preceding enrolment, or planned&#xD;
             receipt during the study period&#xD;
&#xD;
          -  Prior receipt of an investigational malaria vaccine&#xD;
&#xD;
          -  Immunization with more than 1 other vaccines within the past month.&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Hemoglobin SS&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient state, asplenia,&#xD;
             recurrent, severe infections and chronic (more than 14 days) immunosuppressant&#xD;
             medication within the past 6 months (inhaled and topical steroids are allowed)&#xD;
&#xD;
          -  Use of immunoglobulins or blood products within 3 months prior to enrolment&#xD;
&#xD;
          -  Pregnancy, lactation or intention to become pregnant during the study&#xD;
&#xD;
          -  A history of allergic disease or reactions likely to be exacerbated by malaria&#xD;
&#xD;
          -  Contraindications to the use of the first-line anti-malarial medications:&#xD;
             artemether/lumefantrine or atovaquone/proguanil.&#xD;
&#xD;
          -  History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in&#xD;
             situ)&#xD;
&#xD;
          -  History of serious psychiatric condition that may affect participation in the study&#xD;
&#xD;
          -  History of epileptic seizures&#xD;
&#xD;
          -  Any other serious chronic illness requiring hospital specialist supervision&#xD;
&#xD;
          -  Suspected or known current alcohol abuse as defined by an alcohol intake of greater&#xD;
             than 60 g (men) or 40 g (women) per day&#xD;
&#xD;
          -  Suspected or known injecting drug abuse in the 5 years preceding enrolment&#xD;
&#xD;
          -  Seropositive for hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
          -  Seropositive for hepatitis C virus (antibodies to HCV)&#xD;
&#xD;
          -  Falling in moderate risk or higher categories for fatal or non-fatal cardiovascular&#xD;
             event within 5 years (&gt;10%) determined by non-invasive criteria for cardiac risk&#xD;
&#xD;
          -  Abnormal electrocardiogram on screening: pathologic Q wave and significant ST-T wave&#xD;
             changes, left ventricular hypertrophy, non-sinus rhythm except isolated premature&#xD;
             atrial contractions, right of left bundle branch block, advanced A-V heart block&#xD;
             (secondary or tertiary)&#xD;
&#xD;
          -  A QT/QTc interval &gt; 450 ms&#xD;
&#xD;
          -  Volunteers unable to be closely followed for social, geographic or psychological&#xD;
             reasons&#xD;
&#xD;
          -  Any clinically significant abnormal finding on biochemistry or haematology blood&#xD;
             tests, urinalysis or clinical examination&#xD;
&#xD;
          -  Any other significant disease, disorder or finding which, in the opinion of the&#xD;
             Investigator, may significantly increase the risk to the volunteer because of&#xD;
             participation in the study, affect the ability of the volunteer to participate in the&#xD;
             study or impair interpretation of the study data&#xD;
&#xD;
        Additional exclusion criteria for NI group only:&#xD;
&#xD;
          -  History of P. falciparum malaria&#xD;
&#xD;
          -  History of long term residence (&gt;5 years) in area known to have significant&#xD;
             transmission of P. falciparum&#xD;
&#xD;
          -  Presence of sickle cell trait&#xD;
&#xD;
          -  Known thalassemia or thalassemia trait&#xD;
&#xD;
        Exclusion Criterion on Day of Challenge or Day before Challenge&#xD;
&#xD;
          -  Acute disease, defined as moderate or severe illness with or without fever&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Lell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche Médicale de Lambaréné</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Recherches Médicales de Lambaréné</name>
      <address>
        <city>Lambaréné</city>
        <zip>BP 118</zip>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gabon</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>August 27, 2014</study_first_submitted>
  <study_first_submitted_qc>September 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2014</study_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasmodium falciparum malaria</keyword>
  <keyword>Malaria</keyword>
  <keyword>PfSPZ Challenge</keyword>
  <keyword>Controlled Human Malaria Infection (CHMI)</keyword>
  <keyword>Sickle Cell Trait</keyword>
  <keyword>Sporozoites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
    <mesh_term>Sickle Cell Trait</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02237586
org study id: LACHMI-001
nct id: NCT02237586
lead sponsor: 
collaborator: 
collaborator: 
has dmc: Yes
The study is designed to establish infectivity of Plasmodium falciparum sporozoites (PfSPZ)
      via intravenous (IV) administration in three groups with different malaria immunity-status:

        1. Adults with a history of lifelong malaria exposure without sickle cell trait (HbAA)

        2. Adults with a history of lifelong malaria exposure with sickle cell trait (HbAS)

        3. Adults without previous malaria episodes without sickle cell trait (HbAA)

      Initially a dose of 3,200 PfSPZ will be given and the time until thick blood smear positivity
      after challenge will be assessed. If in any of the groups with a history of lifelong malaria
      exposure, 50% or less of individuals become thick blood smear positive during the 28 days
      post injection of PfSPZ Challenge, the dose will be increased 4-fold to 12,800 PfSPZ in this
      group.
LACHMI-001 is a partially-blinded, human pilot trial to study immunity against P. falciparum
      malaria in a controlled infection setting. The main objective is to characterise the role of
      sickle cell trait and naturally acquired immunity in development of malaria, defined by
      positive smear for P. falciparum and signs or symptoms associated with malaria. Three groups
      of volunteers will receive radical cure treatment and subsequently PfSPZ Challenge by IV
      administration. The groups are:

        1. Adults with naturally acquired immunity and HbAA (Group IA, n=10-20)

        2. Adults with naturally acquired immunity and HbAS (Group IS, n=10-20)

        3. Adults without previous exposure to malaria and HbAA (Group NI, n=5)

      The initial challenge dose of 3,200 PfSPZ administered once intravenously leads to consistent
      infection in naïve adults (15/15 in prior studies) and thus should infect all volunteers in
      Group 3. However, volunteers with naturally acquired immunity or sickle cell trait might
      require a higher dose. Thus if 50% or less of volunteers become parasitemic in Groups IA or
      IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. All
      volunteers will be healthy adults aged 18 to 30 years. Safety and infectivity data will be
      collected for each of the regimens and dose-levels. Effective treatment is initiated
      immediately upon development of parasitemia together with the presence of symptoms associated
      with malaria.

      Laboratory staff reading blood films and processing samples will be blinded to group
      allocation. Volunteers and clinical investigators will be blinded to group allocation among
      the IA and IS groups.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Basic Science
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Days from inoculation to start of malaria episode
time frame: From day of injection until day 28
description: The time from parasite inoculation to first detection of malaria will be assessed by thick blood film microscopy and a clinical questionnaire. Malaria is defined as both parasitemia and clinical symptoms suggestive of malaria.
measure: Frequency, incidence and nature of adverse events
time frame: From day of injection until day 28
description: The safety of PfSPZ Challenge administered IV and the resultant P. falciparum infection will be assessed by analysing actively and passively collected data from clinical review of volunteers and laboratory measurements.
measure: Dynamics of P. falciparum parasite growth
time frame: From day 6 after injection until approximately day 28
description: The dynamics of P. falciparum parasite growth following administration of PfSPZ Challenge is assessed by analyzing parasite multiplication rates using highly sensitive qPCR for P. falciparum DNA. Measurements will be used to model parasite kinetics and to estimate the number of infected liver cells.
measure: Cellular and humoral immune responses against parasites
time frame: From screening until 6 months
description: Cellular and humoral immune responses against parasites will be assessed by individual and collective results of cytometry, enzyme-linked immunospot analysis (ELISpot), enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), inhibition of sporozoite invasion of hepatocytes assay (ISI), quantification of erythrophagocytosis, B-cell typing and isolation as well as protein microarray.
measure: Stage specific expression patterns of parasite genes
time frame: From screening until 6 months
description: Stage specific expression patterns of parasite genes will be assessed by RNA quantification using reverse transcriptase PCR (rtPCR) and transcriptional profiling on microarray and sequencing platforms. Differences in miRNA expression between AA and AS erythrocytes will be determined and related to multiplication rates.
arm group label: Group IA
arm group type: Experimental
description: Adults with naturally acquired immunity and HbAA (Group IA, n=10)
As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria.
arm group label: Group IS
arm group type: Experimental
description: Adults with naturally acquired immunity and HbAS (Group IS, n=10)
As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria.
arm group label: Group NI
arm group type: Experimental
description: Adults without previous exposure to malaria and HbAA (Group NI, n=5)
As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge administered once intravenously should lead to consistent infection in naïve adults (15/15 in prior studies) and thus should infect all volunteers in Group NI. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria.
intervention type: Biological
intervention name: PfSPZ Challenge
description: live, aseptic, cryopreserved P. falciparum sporozoites
arm group label: Group IA
arm group label: Group IS
arm group label: Group NI
criteria: 
gender: All
minimum age: 18 Years
maximum age: 30 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Bertrand Lell, MD
role: Principal Investigator
affiliation: Centre de Recherche Médicale de Lambaréné
facility: 
country: Gabon
responsible party type: Sponsor
mesh term: Infections
mesh term: Malaria
mesh term: Malaria, Falciparum
mesh term: Sickle Cell Trait